A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Clinical trial NCT07294508 · RECRUITING
Trial details
- NCT number
- NCT07294508
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-27
- Primary completion
- 2028-01-15
- Enrollment
- 706
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.